KRAS Status Predicts Response to Cetuximab/FOLFIRI

(00:05:28) ASCO, 2008 Jun 1, Mary Ellen Schneider

Dr. Eric Van Cutsem is Professor of Medicine, University Hospital Gasthuisberg, Leuven, Belgium.

In the CRYSTAL trial, mCRC patients with KRAS wild-type tumors experienced a 32% decrease in the risk of progression and a 59% response rate with cetuximab/FOLFIRI therapy, but those with mutated KRAS showed no benefit from the combination. 

See related videos to:
ASCO 2008, Clinical Trials

Related Links

View related Abstract No. 2 »
News Story: KRAS Mutation in Colorectal Cancer Rules Out Treatment Success With Cetuximab »